Loading company…
ID 405104907 · FY 2018–2024 · 7 years
საქმიანობის ძირითადი მიმართულებაა მედიკამენტებით საბითუმო ვაჭრობა და მედიკამენტებთან დაკავშირებული საპრომოციო მომსახურება
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| Net Cash from Operating Activities | 265 | 465 | 75 | 91 | 27 | 398 | -265 | nmf |
| Net Cash used in Investing Activities | 22 | 0 | 0 | -23 | -44 | 0 | -3 | nmf |
| Free Cash Flow (OCF − Capex proxy) | 286 | 465 | 75 | 69 | -17 | 398 | -267 | nmf |
| Net Cash from Financing Activities | -346 | -230 | -147 | -85 | -37 | -150 | -59 | -25.5% |
| Net Change in Cash (before FX) | -60 | 235 | -72 | -16 | -55 | 247 | -326 | +32.8% |
| Effect of FX on Cash | 0 | 5 | 94 | -44 | -17 | 13 | -5 | nmf |
| Net Change in Cash (incl. FX) | -60 | 240 | 22 | -60 | -72 | 261 | -331 | +33.1% |
| Cash at Beginning of Year | 140 | 80 | 320 | 342 | 282 | 210 | 471 | +22.5% |
| Cash at End of Year | 80 | 320 | 342 | 282 | 210 | 471 | 139 | +9.7% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).